GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luye Pharma Group Ltd (FRA:LUP) » Definitions » Additional Paid-In Capital

Luye Pharma Group (FRA:LUP) Additional Paid-In Capital : €557.5 Mil(As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Luye Pharma Group Additional Paid-In Capital?


Luye Pharma Group's quarterly additional paid-in capital increased from Dec. 2023 (€534.2 Mil) to Jun. 2024 (€544.3 Mil) and increased from Jun. 2024 (€544.3 Mil) to Dec. 2024 (€557.5 Mil).

Luye Pharma Group's annual additional paid-in capital increased from Dec. 2022 (€416.6 Mil) to Dec. 2023 (€534.2 Mil) and increased from Dec. 2023 (€534.2 Mil) to Dec. 2024 (€557.5 Mil).


Luye Pharma Group Additional Paid-In Capital Historical Data

The historical data trend for Luye Pharma Group's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luye Pharma Group Additional Paid-In Capital Chart

Luye Pharma Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 130.98 238.43 416.62 534.17 557.50

Luye Pharma Group Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 416.62 475.73 534.17 544.27 557.50

Luye Pharma Group Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Luye Pharma Group Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Luye Pharma Group's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Luye Pharma Group Business Description

Traded in Other Exchanges
Address
Hongqiao Road 1438, 22/F, Gubei International Fortune Center II, Changning District, Shanghai, CHN, 264003
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, Cardiovascular system drugs, Alimentary tract and metabolism drugs and Central nervous system drugs. It derives maximum revenue from the sale of Oncology drugs.

Luye Pharma Group Headlines

No Headlines